Influences Shaping Clinicians’ Monoclonal Antibody and Immune Checkpoint Inhibitor Preparation and Administration Management Practices: A Systematic Review

Ballard, Angela; Thamm, Carla; Ogle, Theodora; Phillips, Jane L.

doi:10.1016/j.soncn.2024.151583

Cited by 2 publications

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan

Shomura,

Okabe,

Sakakibara

et al. 2024

Hepatology Research

View full text Add to dashboard Cite

AimThis study aimed to comprehensively assess the incidence of immune‐related adverse events (irAEs) and the detection systems in place for patients with liver cancer undergoing treatment with immune checkpoint inhibitors (ICIs), using a self‐administered anonymous questionnaire. The questionnaire was designed to gather crucial insights into the management of irAEs in these patients.MethodsA self‐administered anonymous questionnaire was sent to 456 liver disease collaborative base hospitals and cancer care coordination base hospitals in Japan.ResultsResponses were received from 112 facilities, indicating a response rate of 25%. The region with the highest response rate was Kanto (22%, 24 sites), followed by Kyushu (19%, 21 sites), Chubu (14%, 15 sites), and Kinki (14%, 15 sites). The number of patients with hepatocellular carcinoma (HCC) who received ICI treatment varied, with a mean ± SD of 20.4 ± 19.4 cases per year per facility. The number of full‐time physicians who provided ICI treatment for HCC was 4.2 ± 3.3 (mean ± SD), ranging from 0 to 24 per facility. Of these, the majority included hepatologists and oncologists, whose numbers were 3.3 ± 2.4 (mean ± SD) (range, 0–11) and 0.8 ± 1.0 (0–3), respectively. Gastroenterologists and internal medicine specialists participated in the treatment at some facilities.ConclusionsThe survey results revealed that physicians administered ICI therapy for an average of 20 HCC cases per institution, with more than 17 types of irAEs reported. The most common irAEs were hepatic dysfunction, followed by thyroid dysfunction, skin disorders, interstitial pneumonia, and renal dysfunction.

show abstract

Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan

Shomura,

Okabe,

Sakakibara

et al. 2024

Hepatology Research

View full text Add to dashboard Cite

show abstract

Monoclonal Antibody Therapies in Cancer Immunotherapy

Thanawiroon,

Yingngam

2024

Advances in Medical Diagnosis, Treatment, and Care

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) can significantly improve patient outcomes in cancer treatment while reducing related side effects, offering a targeted therapy alternative to traditional treatment regimens. This chapter describes the development, mechanisms, and applications of mAb therapies as critical components of cancer immunotherapy. The chapter covers the history and progression of the use of mAbs in therapy, their multiple mechanisms—such as immune checkpoint inhibitors, the acumen for cancer antigens and antibody—drug conjugates—and the newest developments in this area. Moreover, this chapter reviews relevant case studies and trial data to compare the impact of these agents on various malignancies. This chapter concludes with a summary of the current challenges—developed resistance, on the one hand—and toxic side effects, e.g., cytokine release syndrome and neurotoxicity, on the other—and prospective avenues of the field.

show abstract

Influences Shaping Clinicians’ Monoclonal Antibody and Immune Checkpoint Inhibitor Preparation and Administration Management Practices: A Systematic Review

Cited by 2 publications

References 45 publications

Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan

Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan

Monoclonal Antibody Therapies in Cancer Immunotherapy

Contact Info

Product

Resources

About